Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: IV fluids Clear all
Completed Phase 1 Interventional

Rapamycin Plus Bevacizumab in Advanced Cancers

NCT00667485
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer
Interventions
Rapamycin (liquid), Bevacizumab, Rapamycin (Tablets)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Sep 4, 2026, 1:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed

NCT02339155
View directory record Official record
Conditions
Infections, Bacterial
Interventions
AVA, Raxibacumab, Diphenhydramine
Biological · Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 65 Years
Enrollment
573 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
Edgewater, Florida • Overland Park, Kansas • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 4, 2026, 1:32 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS

NCT05938036
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS)
Interventions
ALT-100 mAb, ALT-100 (Placebo)
Drug
Lead sponsor
Aqualung Therapeutics Corp.
Industry
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 4, 2026, 1:32 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA

NCT03523117
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferric carboxymaltose, Ferrous Sulfate
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
16
States / cities
Little Rock, Arkansas • Doral, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Sep 4, 2026, 1:32 AM EDT
Completed Phase 4 Interventional Results available

Alvimopan as a Rescue Treatment of Postoperative Ileus

NCT04405037
View directory record Official record
Conditions
Ileus, Gastrointestinal Dysfunction
Interventions
Alvimopan
Drug
Lead sponsor
Scott Steele
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Sep 4, 2026, 1:32 AM EDT
Completed Phase 2 Interventional Results available

Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma

NCT00101101
View directory record Official record
Conditions
Lymphoma
Interventions
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Dexamethasone, Autologous Tumor Cell-Based Vaccine, IL-2
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Sep 4, 2026, 1:32 AM EDT
Completed Not applicable Interventional

Randomized Trial of Restrictive Versus Liberal Perioperative Fluid Management for Patients Undergoing Pancreatic Resection

NCT01058746
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
restrictive perioperative fluid management, Liberal perioperative fluid management
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 4, 2026, 1:32 AM EDT
Recruiting No phase listed Observational

An Exosomal microRNA Signature for Preoperative Staging in Colon Cancer

NCT07255729
View directory record Official record
Conditions
Colon Cancer
Interventions
Diagnostic Test: EXPOSE assay（Small RNA-seq of exosomal miRNAs）, Diagnostic Test: EXPOSE RT-qPCR panel
Diagnostic Test
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 4, 2026, 1:32 AM EDT
Terminated Phase 2 Interventional

Trial Comparing Early Laparoscopic Enterolysis Versus Nonoperative Management for High-grade SBO

NCT02692638
View directory record Official record
Conditions
Small Bowel Obstruction
Interventions
Early laparoscopic enterolysis, nonoperative management
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 4, 2026, 1:32 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With Influenza

NCT01063933
View directory record Official record
Conditions
Influenza
Interventions
Peramivir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2012
U.S. locations
29
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2011 · Synced Sep 4, 2026, 1:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

NCT02489448
View directory record Official record
Conditions
Breast Neoplasms
Interventions
MEDI4736
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Sep 4, 2026, 1:32 AM EDT
Terminated Phase 3 Interventional Results available

Alvimopan as Rescue in Post op Ileus

NCT02742181
View directory record Official record
Conditions
Colorectal Surgery, Ileus
Interventions
Alvimopan, Control Group
Drug · Other
Lead sponsor
Sharon Stein
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Sep 4, 2026, 1:32 AM EDT
No Longer Available No phase listed Expanded access Accepts healthy volunteers

Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion

NCT01238276
View directory record Official record
Conditions
Infection, Soft Tissue, Infection, Wound, Cellulitis, Diabetic Foot Ulcer
Interventions
Cefazolin, Silberg Tissue Preparation System
Drug · Device
Lead sponsor
Sonescence, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Sebastopol, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Sep 4, 2026, 1:32 AM EDT
Completed Phase 1 Interventional

Galantamine Effects on Nicotine Responses in Smokers

NCT01417429
View directory record Official record
Conditions
Smoking, Tobacco Withdrawal
Interventions
Galantamine, IV Nicotine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Sep 4, 2026, 1:32 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)

NCT05095727
View directory record Official record
Conditions
Glycogen Storage Disease
Interventions
mRNA-3745
Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
6 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
Farmington, Connecticut • Boston, Massachusetts • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 4, 2026, 1:32 AM EDT
Not yet recruiting Not applicable Interventional

Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell Lung Cancer

NCT06816979
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Lumbar Puncture, Magnetic Resonance Imaging
Procedure · Device
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 4, 2026, 1:32 AM EDT
Completed Not applicable Interventional Results available

AccuCath™ Intravenous (IV) Device Used by Vascular Access Team (VAT)

NCT01937195
View directory record Official record
Conditions
Vascular Access Complication
Interventions
AccuCath Intravenous Catheter System
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years to 89 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Lewisburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 4, 2026, 1:32 AM EDT
Completed Phase 1Phase 2 Interventional

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

NCT04722887
View directory record Official record
Conditions
Alpha1-Antitrypsin Deficiency
Interventions
Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human)
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 4, 2026, 1:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis

NCT00891527
View directory record Official record
Conditions
Pulmonary Veno Occlusive Disease
Interventions
Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Sep 4, 2026, 1:32 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma

NCT03389477
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Palbociclib, Cetuximab, Cisplatin, Intensity-Modulated Radiation Therapy, Tumor biopsy, Peripheral blood draw
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 4, 2026, 1:32 AM EDT
Completed Not applicable Interventional

Effect of Physiologic Insulin Administration on Cognition

NCT06424652
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Blood draws, Hyperinsulinemic Euglycemic Clamp Technique Insulin Sensitivity test, Resting Metabolic Rate (RMR)
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
65 Years to 75 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 4, 2026, 1:32 AM EDT
Terminated No phase listed Observational

Compensatory Reserve Index (CRI) for Management of COVID-19

NCT04457817
View directory record Official record
Conditions
COVID
Interventions
CRI
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Sep 4, 2026, 1:32 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Infusion Flow Rates and Blood Sampling

NCT02021617
View directory record Official record
Conditions
Intraosseous Access, Infusion Rates, Intraosseous Blood, Venous Blood
Interventions
Intraosseous access
Device
Lead sponsor
Vidacare Corporation
Industry
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Spring Branch, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2013 · Synced Sep 4, 2026, 1:32 AM EDT
Completed No phase listed Observational

Neurophysiology and Anatomy of Severe Intraventricular Hemorrhage (IVH)

NCT00817310
View directory record Official record
Conditions
Intracranial Hemorrhages, Prematurity
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
Up to 14 Days
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Sep 4, 2026, 1:32 AM EDT